



Jean-Luc Bélingard, member of the Board of Directors of *Inserm*

Paris (France), 7 February 2006 – Jean-Luc Bélingard, Chairman and CEO of the Ipsen Group has been appointed a member of the Board of Directors of the French National Institute for Health and Medical Research (*Inserm, Institut national de la santé et de la recherche médicale*) as a key representative from the industry sector.

Jean-Luc Bélingard graduated from the HEC business school in 1971 and was awarded an MBA from Cornell University (United States) in 1974. Before taking up the position of Chairman and CEO of the Ipsen Group in January 2002, he was a member of the Executive Board and CEO of BioMérieux-Pierre Fabre (from 1999 to 2001). In 1982, Jean-Luc Bélingard joined the Roche Group, where he held several positions including head of the diagnostics division. He was also a member of the Executive Committee. Jean-Luc Bélingard is also Director and Chairman of the Compensation Committee of the Laboratory Corporation of America (Burlington, North Carolina), Director of Applera Corporation (Norwalk, Connecticut), Director and member of the Compensation Committee of ExonHit (France), Director and member of the Compensation Committee of NicOx (France) and adviser to the French government on foreign trade. Jean-Luc Bélingard is Delegate General and spokesman for G5, an association encompassing the principal French pharmaceutical companies, namely Sanofi-Aventis, Servier, Pierre Fabre and Ipsen.

Ipsen

Ipsen is a European pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. The Company's development strategy is based on a combination of products in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), which are growth drivers, and primary care products, which contribute significantly to its research financing. This strategy is also supported by an active policy of partnerships. The location of its four R&D centres (Paris, Boston, Barcelona, London) gives the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 650 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. Ipsen shares are traded in Compartment A of Eurolist by Euronext™ (stock code: IPN, ISIN code: FR0010259150).

For further information:

Ipsen

Didier Véron, Director of Public Affairs and Corporate Communications

Tel.: +33 (0)1 44 30 42 38 - Fax: +33 (0)1 44 30 42 04

e-mail: didier.veron@ipsen.com

www.ipsen.com